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Objective: The purpose of this study was to evaluate postchemoradiotherapy surgery
in stage IIIB non–small cell lung cancer. 
Methods: Forty patients with stage IIIB non–small cell lung cancer were included in
this phase II study. A preoperative diagnosis of stage IIIB cancer was based on medi-
astinoscopy or a thoracotomy in all patients. Induction treatment included two cycles
of cisplatin (100 mg/m2, day 1), 5-fluorouracil (1 g/m2, days 1-3), and vinblastine (4
mg/m2, day 1) combined with 42 Gy of hyperfractionated radiotherapy delivering 21
Gy in two sessions. Patients with a clinical response were offered surgery.
Results: The minimum follow-up for survivors was 48 months. Thirty patients had a T4
lesion and 18 had N3 disease. Twenty-nine patients (73%) had a clinical objective tumor
response after induction treatment. These 29 patients underwent thoracotomy, and a
complete resection was performed in 23 (58%). Two postoperative deaths occurred
(7%). Four patients had a pathologic complete response at the time of surgery (10%).
The 5-year survival is 19% for the overall population. When only patients who had per-
sistent viable tumor cells at surgery are considered (n = 25), the 5-year survival is 28%.
The 5-year survival is 42% for patients having no mediastinal lymph node involvement
at the time of surgery and being treated with complete resection. 
Conclusion: This study shows that surgery, when feasible, is associated with a
28% long-term survival for patients in whom chemoradiotherapy alone fails to
control disease. 
Stage IIIB disease is considered inoperable and the patients are usuallytreated with chemoradiotherapy.1-3 An analysis of relapse sites has shownthat locoregional failure is the major stumbling block in these patients4because the 1-year locoregional control rate was only 17% for patientstreated with chemoradiotherapy. In the same trial, chemotherapy dramat-ically decreased the rate of distant metastasis from 67% to 45%. Since
then, postinduction surgery has been investigated as a possible alternative means of
improving locoregional control of stage IIIB disease. Postinduction surgery was
reported to be feasible and complete resection possible in more than 50% of cases.
Only a few studies,5-7 however, included more than 20 patients, and the median follow-
up was short in all of them. The long-term evaluation of postinduction surgery in a
large phase II study has yet to be attempted. The aim of the present phase II study was
to evaluate the long-term efficacy of postinduction surgery for patients with stage IIIB
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non–small cell lung cancer (NSCLC), particularly focusing on
patients with viable tumor cells after induction treatment. 
Patients and Methods 
Patient Selection
From April 1993 to June 1996, 40 patients with stage IIIB NSCLC8
diagnosed at mediastinoscopy or thoracotomy were included in the
present prospective clinical trial. Potentially resectable disease after
induction treatment was mandatory for inclusion. Table 1 describes
the patient population selected. Further eligibility criteria included
a Karnofsky index above 70%, weight loss of less than 10%, age
below 70 years, a granulocyte and platelet count of more than
2000/mm3 and more than 100,000/mm3, respectively, a hemoglobin
value of more than 10 g/dL, a serum creatinine value of less than
100 µm/L, a predicted postoperative forced vital capacity of more
than one third the value in theory, no previous malignancy (except
Figure 1. Study design. 5 FU, 5-Fluorouracil; CDDP, cis-diaminedichloroplatinum; D, day.
TABLE 1. Patient selection: Stage IIIB subgroups
Eligible: Potentially resectable Ineligible: Definitively 
T4 involvements (T41) unresectable T4 tumors (T42)
Intrapericardial pulmonary Malignant pleural effusion
artery
Trachea Malignant pericardial effusion
Carina Diffuse mediastinal involvement*
Left atrium Infiltration of the heart (except 
left atrium)
Superior vena cava Vertebrae 
Esophageal involvement
N3 disease 
*Mediastinal involvement that did not appear to be potentially resectable
after induction therapy.
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basocellular cutaneous cancer), and no prior treatment for lung can-
cer. This study was approved by the ethical committee and all
patients had to sign a written informed consent form before inclu-
sion. During the same period, a total of 210 patients with stage IIIB
NSCLC have been seen in our institutions. 
Pretreatment Evaluation
Pretreatment evaluation included a medical history, physical examina-
tion, complete blood cell count, complete serum chemistries, electro-
cardiogram, ventilation-perfusion nuclide scintigraphy, and lung
function tests. Tumor staging was performed by chest radiography; a
computed tomographic (CT) scan of the chest, adrenal glands, liver,
and brain; examination with a fiberoptic bronchoscope; and cervical
mediastinoscopy or thoracotomy. Thoracoscopy, esophageal ultra-
sound endoscopy, angiographic CT scan, and magnetic resonance
imaging were performed, if necessary, for better pretreatment staging
and to assess resectability. 
Preoperative Chemoradiotherapy (Figure 1)
A total dose of 42 Gy was given to the primary tumor and medi-
astinal lymph nodes in two sessions of accelerated hyperfraction-
ated radiotherapy. Two doses of 1.5 Gy were given daily over 7 days
up to a total dose of 21 Gy via anteroposterior fields. This was fol-
lowed by a rest of 10 to 12 days. A second dose of 21 Gy was then
delivered by means of the same schedule, but the first 9 Gy was
delivered via anteroposterior fields, and the remaining 12 Gy was
delivered via oblique fields. The target volume was delimited on the
initial chest x-ray film and CT scan of the thorax. The radiation
field included the primary tumor with a 1.5-cm margin, the ipsilat-
eral pulmonary hilum, upper and medium mediastinal lymph nodes,
and homolateral supraclavicular lymph nodes. 
Two cycles of chemotherapy were to be administered on days 1
and 31; the first of the two chemotherapy cycles was delivered con-
comitantly with radiotherapy, but not the second cycle. Chemo-
therapy consisted in 5-fluorouracil, 1 g/m2 in 24 hours over a 72-hour
period in a continuous infusion (D1 and D31), cisplatin, 100 mg/m2
given 2 to 6 hours after the start of 5-fluorouracil, and vinblastine, 4
mg/m2. The second chemotherapy course on day 31 was postponed
if patients had a granulocyte count of less than 1500/mm3 or a platelet
count of less than 100,000/mm3 and until these values were reached. 
Response and Toxicity of Chemoradiotherapy
Response to induction treatment was assessed by means of the stan-
dard World Health Organization (WHO) criteria. Complete
response to induction treatment was defined as the complete eradi-
cation of tumor. Partial response was defined as a 50% reduction in
the sum of the products of all measurable lesions or a decrease
(50%) in the size of assessable but nonmeasurable lesions. Stable
disease was defined as a change in the sum of the products of all
measurable lesions, between less than a 50% reduction and less
than 25% progression. Definitive progressive disease was defined
as a 25% increase in the sum of the products of tumor parameters
or the appearance of new tumor lesions. Toxicity induced by pre-
operative treatment was assessed by means of WHO criteria. 
Postchemoradiotherapy Staging 
At day 65, restaging was done in all patients with a chest x-ray film,
CT scan of the thorax, the upper part of the abdomen, and brain, and
examination with a fiberoptic bronchoscope. This new staging pro-
cedure was performed to assess the clinical tumor response and
to select patients for surgery. Lung function tests and ventilation-
perfusion nuclide scintiscans were performed to assess whether
examination results did not contraindicate surgery.
Surgery (Figure 1) 
All patients treated with induction chemoradiotherapy and having
a clinical response were selected for surgery. The surgical
approach was a midline sternolaparotomy in most of the cases.
When the lower part of the trachea or the carina was involved at the
first staging procedure, the surgical approach was a right thoraco-
tomy. A right thoracotomy associated with a laparotomy or a ster-
nolaparotomy was the surgical option in cases of vena caval
involvement. For left-sided tumors, particularly from the left lower
lobe, or when a great vessel was involved on the left side (pul-
monary artery), the surgical approach was a left thoracotomy in
association with either a laparotomy or a sternolaparotomy,
according to the nodal status (N2 or N3). The objective of surgery
was to completely remove all tumor tissue. Lymph node dissection
consisted in the resection of all ipsilateral mediastinal lymph node
stations in all cases. In case of N3 disease, a bilateral mediastinal
lymph node dissection was performed. After lung resection, the
TABLE 3. Results of induction chemoradiotherapy in 40 patients: 
% of 
Results No. % of overall evaluated
Mediastinitis 1 2
Early deaths 3 6
Treatment related 1 2
Progression 2 4
Eligible for evaluation on day 65 36 92 100
Progressive disease 6 12 16
Stable disease 1 2 3
Partial response 27 68 75
Complete response 2 4 6
Eligible for surgery 29 73 80
TABLE 2. Patient characteristics
Characteristic No. (percentage)
Male sex 34 (85%)
Age* (y) 55 (34-69)*
Weight loss > 10% 3 (7%)
Karnofsky index > 90% 34 (85%)
Histology subtype
Adenocarcinoma 13 (32%)
Squamous cell carcinoma 11 (28%)
Large cell carcinoma 16 (40%)
TNM
T4 N0-N2 21 (53%)
T2-3 N3 10 (25%)
T4 N3 9 (22%)
*Median (range).
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bronchial stump was wrapped in a pedicled omental flap in all
cases, to avoid bronchial complications resulting from preopera-
tive chemoradiotherapy and particularly stump insufficiency. 
After surgery and according to pathologic findings, patients were
classified as having had a complete or an incomplete response to
induction treatment and a complete or a partial resection. The status of
mediastinal lymph nodes after induction treatment was also recorded.
Follow-up 
All patients were monitored every 3 months for the first 2 years
from the end of the treatment and every 6 months during the next 3
years. Tests conducted during follow-up visits included a physical
examination, a complete blood cell count and serum chemistry
assessment, and a chest x-ray film. A CT scan of the thorax was
obtained every 6 months after the end of the treatment, and exami-
nation with a fiberoptic bronchoscope was performed every year
after the end of the treatment. 
Statistical Analysis
Survival was measured from the first day of radiotherapy until
death or the last follow-up visit. The postoperative death and mor-
bidity rates are defined as events occurring before hospital dis-
charge. The locoregional control rate is defined as the percentage
of patients free of tumor in the ipsilateral lung, the mediastinum,
or the supraclavicular area. This definition is derived from that pro-
posed by Arriagada and associates.4 Relapse-free survival was the
time from radiotherapy until disease progression. Survival curves
were evaluated by the Kaplan-Meier method.9 Median follow-up
was calculated by the method of Schemper and Smith.10
Multivariate analysis of prognostic factors for survival and relapse
was performed by the Cox model. Multivariate analysis included 4
parameters (10% of the number of patients): pretreatment T, pre-
treatment N, postinduction N, and postinduction T. 
Results 
Patient Characteristics
The present analysis was conducted on April 1, 2000, with
updated data. Median follow-up is 64 months and the mini-
mum follow-up for survivors is 48 months. No patient has
been lost to follow-up. Patient characteristics are summa-
rized in Table 2. The Karnofsky index was more than 90%
in 85% of patients. The histologic type was adenocarcinoma
in 13 (32%) patients, squamous cell carcinoma in 11 (28%)
patients, and large cell carcinoma in 16 (40%) patients. A
brain, upper abdominal, and chest CT scan, a liver ultra-
sound, and a bone scan were performed on all patients.
Surgical thoracic staging (mediastinoscopy or thoracotomy)
was performed on all patients. Thirty patients had a T4
tumor based on evidence obtained at radiologic and surgical
staging. Among these 30 patients, 5 had a T4 N0, 1 a T4 N1,
15 a T4 N2, and 9 a T4 N3 tumor. Nineteen patients had N3
involvement at diagnosis, and 1 of them had supraclavicular
lymph node involvement. Proof of N2 and N3 disease was
based on the histologic analysis of the biopsy specimen
obtained at mediastinoscopy. 
Induction Chemoradiotherapy (Table 3) 
One patient did not receive the planned doses of chemora-
diotherapy because of coagulase-positive staphylococcus-
induced mediastinitis. Three deaths occurred, 2 due to severe
hemoptysis related to locoregional progression (days 46 and
57) and 1 due to grade 4 neutropenia and thrombocytopenia
(day 43). Four patients were therefore not evaluated on day
65. No grade 3/4 esophageal toxicity was noted. Six patients
had grade 3/4 neutropenia. 
A clinical tumor response was obtained in 29 patients
(73%) during chemoradiotherapy (2 clinical complete
responses). Disease was stable in 1 patient but progressed in
6 patients. The 29 (73%) patients who had a clinical tumor
response after induction treatment were therefore eligible
for surgery. Patients who did not have a tumor response (n
= 7) or who had mediastinitis (n = 1) were not eligible for
surgery. 
Surgery 
The median time from the first day of chemoradiotherapy to
surgery was 77 days (range 63-90 days). Twenty-nine patients
underwent a thoracotomy, which revealed unresectable dis-
ease in 5 patients. Tumor resection was therefore feasible in
24 (60%) patients. A pneumonectomy was performed on 18
patients and a lobectomy on 6. Twenty-one patients, includ-
ing all patients with N3 disease at initial staging, underwent a
bilateral mediastinal lymphadenectomy and 3 an ipsilateral
mediastinal lymph node dissection. The postchemoradiother-
apy mediastinal lymph node status was therefore assessable
in all patients treated with surgery. The vena cava was
resected in 4 patients, a great vessel in 3 patients, the left
atrium in 7 patients, the trachea in 3 patients, and the carina
in 3. In 18 patients treated with pneumonectomy, the
bronchial stump was wrapped in a pedicled omental flap. The
postoperative death rate was 7% (2 patients). Postoperative
morbidity affected 7 patients (24%) and included acute respi-
ratory distress syndrome (n = 2), phrenic nerve paralysis (n =
1), prolonged assisted ventilatory support (n = 1), cardiac fail-
ure during surgery (n = 1), persistent pleural effusion (n = 1),
and omental flap necrosis (n = 1). No stump insufficiency nor
morbidity related to laparotomy was noted. The median dura-
tion of the postoperative hospital stay was 20 days. 
Pathologic Findings 
A histologic complete resection was achieved in 23 (58%)
patients. A histologic complete response was obtained in 4
(10%) patients. Ten patients with N2/N3 disease (30%) had a
complete disappearance of mediastinal lymph node involvement 
(mediastinal lymph node down staging) after chemoradio-
therapy. Twenty-five patients who had a clinical objective
tumor response and who had persistent viable tumor cells in
the thorax were submitted to surgery. These 25 patients were
defined as partial responders. Thirteen partial responders
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were classified as postinduction N0/N1. Resection was com-
plete in 20 of these partial responders.
Survival Analysis 
Of the 40 patients, 7 (17.5%) were alive at 48, 53, 54, 67, 72,
and 73 months, and 5 (12.5%) of them were free of disease
at 48, 53, 67, 72, and 73 months. All these 7 patients had per-
sistent viable tumor cells after induction treatment and 6 of
them had no mediastinal lymph node involvement at the time
of surgery (postinduction N0/N1). 
In 8 patients the disease progressed during chemoradio-
therapy. Progression occurred in the primary site (n = 5), bone
(n = 3), brain (n = 2), and liver (n = 1). Of the 29 patients who
underwent thoracotomy, 19 (65%) have had a relapse.
Thirteen (45%) had a distant metastasis as the first relapse
event. The first site of distant metastasis was the contralateral
lung (n = 5), liver (n = 1), bone (n = 3), brain (n = 6), distant
lymph node (n = 1), or another site (n = 2). Five patients had
multiple sites of metastasis. Seven (24%) patients had a
locoregional relapse after surgery. Five (20%) partial respon-
ders had a locoregional relapse. When overall patients are con-
sidered, 12 (30%) have had a locoregional relapse.
Twenty-three percent of the overall population (95% confi-
dence interval [CI]: 11%-41%) had not had a relapse at 5
years. When only partial responders were considered (n = 25),
22% (95% CI: 10%-34%) had not had a relapse at 5 years.
Thirty-three deaths occurred. Of these, 8 (24%) occurred
in patients with no evidence of recurrent disease. These 8
patients died of thrombocytopenia and neutropenia (n = 1),
myocardial infarction (n = 2), and lung insufficiency (n = 5).
Lung insufficiency was related to acute respiratory distress
syndrome (n = 3), pulmonary embolism plus interstitial
pneumonitis (n = 1), and postradiation pneumonitis (n = 1).
Of these, 4 (10%) were directly related to treatment. 
The 5-year overall survival for the 40 patients is 19% (CI
95%: 10%-34%) (Figure 2). The 5-year overall survival is
23% (11%-40%) and 17% (6%-39%) for patients with T4 NX
and TX N3, respectively. The 5-year overall survival is 42%
for postinduction N0/N1 treated with complete resection,
12% for postinduction N2/N3 treated with complete resec-
tion, and 0% for patients who were not treated with complete
resection (P < .001) (Figure 3). A multivariate analysis (Table
4) showed that postinduction mediastinal lymph node status
was the only prognostic factor for survival and relapse (rela-
tive risk for death, 3.1; relative risk for relapse, 4.9; P = .005
and .001, respectively). 
The 4 patients who had a complete response after chemora-
diotherapy died after 5, 6, 58, and 60 months. None of these
patients had a relapse. The 5-year survival is 28% (CI 95%:
14%-47%) for the partial responders (Figure 4) and 35% for
those treated with complete resection (n = 20). The 5-year sur-
vival is 47% for partial responders with postinduction N0/N1.
Two of the 11 patients treated with superior vena caval resec-
tion or a left atrial resection survived 5 years. 
Discussion 
This study shows that surgery can achieve a promising 28%
long-term survival in patients with stage IIIB NSCLC who only
partially responded to chemoradiotherapy (partial responders).
Figure 3. Survival according to postinduction lymph node status
and resection.
Figure 2. Survival of the overall population.
TABLE 4. Multivariate analysis for survival and relapse
Relative risk 
Survival Relapse 
Pretreatment N 1.2 (P = .7) 1.3 (P = .6)
Pretreatment T 1.3 (P = .5) 1.3 (P = .6)
Postinduction N 3.1 (P = .005) 4.9 (P = .001)
Postinduction T 2.1 (P = .06) 2.0 (P = .08)
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Chemoradiotherapy is considered the standard treatment
for stage IIIB NSCLC.1-3 Nevertheless, the locoregional con-
trol rate, defined as the percentage of patients free of residual
tumor in the thorax after treatment, is a modest 17% at 1
year.4 The persistence of viable tumor cells in the primary
tumor site or in the mediastinum after chemoradiotherapy is
a valid marker of treatment failure and death, whatever the
clinical response.11 This was demonstrated in a series of 63
patients with stage III disease treated with chemoradiotherapy
who had persistent viable tumor cells at bronchoscopy. In this
prospective study, the 3-year operative survival was only 3%
for these patients. Because locoregional control is determi-
nant in the outcome of stage III disease, it was the rationale
behind the inclusion of surgery in a multimodality treatment
approach. In this setting, postinduction surgery is considered
a salvage procedure aimed at achieving locoregional control.
Previous studies of multimodality treatment reported 3-year
operative survivals ranging from 24% to 26%, complete
resection rates from 50% to 70%, and locoregional failure
rates of only 20% to 38%.5-7 Our results are in the same
range, with a 3-year operative survival of 28%, a 58% com-
plete resection rate, and a 30% locoregional failure rate. All
together, these results are encouraging when compared with
the large phase III chemoradiotherapy studies conducted by
Le Chevalier,2 Sause,3 and their coworkers, but not convinc-
ing when compared with phase III trials of chemoradiother-
apy performed in well-selected populations.12,13
Because the persistence of viable tumor cells after
chemoradiotherapy is considered a marker of treatment fail-
ure, we looked at the effect of surgery in patients who only
partially responded to chemoradiotherapy. Surprisingly,
surgery successfully salvaged a population rarely considered
curable and obtained an interesting 28% long-term survival.
A comparable result was achieved in the Southwest Oncology
Group (SWOG) study,5 which reported a similar outcome for
patients with a pathologic complete response after chemora-
diotherapy and those with persistent viable tumor after
chemoradiotherapy and treated by surgery. In the German
study,6 the 4-year survival was 46% for patients treated with
surgery and having persistent viable tumor cells after
chemoradiotherapy. These data suggest that surgery is an effi-
cient salvage treatment for patients with stage IIIB NSCLC
with viable residual disease after chemoradiotherapy alone.
On the other hand, none of the 4 patients who had a histologic
complete response after induction treatment are alive. The
rationale for surgery is questionable in these patients in whom
preoperative evaluation of a pathologic complete response,
with the use of new staging techniques such as positron emis-
sion tomographic scanning, is probably required. 
Previous studies5,6,13 have reported that the mediastinal
lymph node status after induction treatment had a prognostic
significance for patients treated with postinduction surgery.
In a study including 42 patients with stage IIIAN2 disease
treated with multimodality therapy, Choi and colleagues14
reported that the degree of lymph node down staging was
translated into a survival benefit since the 5-year survivals
were 79%, 42%, and 18% for postoperative tumor stages 0/I,
II, and III, respectively. In the SWOG study,5 the strongest
predictor of long-term survival after thoracotomy was the
absence of tumor in the mediastinal nodes (3-year survival
44% vs 18%; P = .0005). In the German study, 4-year sur-
vivals were 38% and 15% (P = .11) for postinduction N0/N1
and N2/N3 patients, respectively. Multivariate analysis per-
formed in our study fully confirms these data since it shows
that the presence of mediastinal lymph node involvement
after induction treatment is the most relevant prognostic indi-
cator. Altogether these studies suggest that the postinduction
N2/N3 status is a marker of microscopic metastatic disease
and that surgery is not associated with a significant long-
term survival in these patients. On the other hand, the
absence of mediastinal lymph node involvement after induc-
tion therapy for patients with stage III disease is always asso-
ciated with a long-term survival of more than 30% after
surgery, whatever the initial T stage. 
Specific procedures such as bilateral lymphadenectomy,
extrapulmonary resections, and median sternotomy are
required for postinduction surgery for patients with stage
Figure 4. Survival of partial responders.
TABLE 5. Review of resections and survivals of patients with
stage IIIB cancer treated with postinduction surgery
SWOG5 WGCC6 GLCCG7 CEBI
No. of cases 51 42 29 40
Clinical response rate 59%* 64%* 62% 73%
Resection rate 24% 45% 68% 58%
Survival 24% (3 y) 26% (4 y) 26% (3 y) 19% (5 y)
SWOG, Southwest Oncology Group; WGCC, West German Cancer Center;
GLCCG, German Lung Cancer Cooperative Group; CEBI, current study.
*Including stages IIIA and IIIB.
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IIIB NSCLC. Initial reports14 documented high rates of post-
operative complications (46%) and mortality (8.6%) in
patients treated with preoperative chemoradiotherapy. In
their respective studies, Albain,5 Eberhardt,6 and their asso-
ciates reported high rates of non–cancer-related deaths (25%
and 26% of the overall population). Our study confirms this
finding inasmuch as 8 (20%) deaths occurred in patients in
complete remission. Five of these deaths were due to lung
insufficiency and 2 to myocardial infarction. Our study and
others reported a higher rate of acute respiratory distress syn-
drome or pneumonitis after multimodality treatment com-
pared with standard lung resection alone. These data indicate
that patient management needs to be improved to decrease
toxicities. In particular, radiotherapy schedules, surgical pro-
cedures, and postoperative care (intensive care and long-term
follow-up) need to be reappraised and redefined to avoid
these complications. Previous studies suggested that preop-
erative chemotherapy and/or radiotherapy could increase the
rate of bronchial stump insufficiency.15 Some teams16,17 per-
form omentoplasty to avoid this complication. In the present
study, the bronchial stump was wrapped in a pedicled omen-
tal flap in 18 cases. No stump insufficiency was noted with
this procedure, which suggests that it is an efficient way of
avoiding stump insufficiency. 
Stage IIIB NSCLCs are classified as “unresectable locally
advanced NSCLC” in the current TNM staging system.18
Nevertheless, our study and previous studies (Table 5) show
that surgery makes it possible both to achieve a high rate of
complete remission and to salvage patients with residual dis-
ease after chemoradiotherapy. This argues for a change in the
TNM classification. In a recently published proposition,19,20
selected patients with stage IIIB disease and clinically
detectable N2 disease were classified in a subgroup desig-
nated “potentially resectable.” Further studies are needed to
confirm the relevance of this new subclassification. 
In conclusion, this study suggests that postchemoradio-
therapy surgery is an efficient salvage procedure for selected
patients with stage IIIB disease who are partial responders
without mediastinal lymph node involvement at the time of
surgery. Altogether these data suggest that postinduction TN
status is more accurate than pretreatment TN status to guide
the indications for surgery for patients with stage IIIB dis-
ease. This study raises several questions: What is the best pre-
operative strategy to increase the rate of mediastinal lymph
node down staging? How can toxicity induced by multi-
modality treatment be lessened? Faced with such toxicity,
should surgery be performed in patients having a complete
response,and how can they be identified preoperatively? 
We thank Lorna Saint-Ange for editing. 
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